22 February 2016 - Patients with advanced forms of skin cancer should have the option of treatment with Bristol-Myers Squibb’s immunotherapy Opdivo on the NHS in England and Wales after cost regulators issued final guidance endorsing the drug’s use in this setting.

For more details, go to: http://www.pharmatimes.com/Article/16-02-22/Final_NICE_nod_for_Opdivo_in_skin_cancer.aspx